Faculty of Biological Sciences

Research Bulletin

Study finds non-genetic cancer mechanism

27th July 2015

Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.

Study finds non-genetic cancer mechanism

The discovery is a major breakthrough because, until now, genetic aberrations have been seen as the main cause of almost all cancer.

The research, published today in the journal Oncogene, demonstrates that protein imbalance is a powerful prognostic tool, indicating whether or not patients are likely to respond to chemotherapy and whether a tumour is likely to spread to other sites.

The findings also open the possibility of new therapies aimed at measuring and preventing dangerous imbalances in cells.

Lead author Professor John Ladbury,Dean of the University of Leeds’ Faculty of Biological Sciences and Professor of Mechanistic Biology, said: “There has been huge investment in sequencing the human genome with the idea that if we get all the relevant genetic information we can predict whether you have a predisposition to cancer and, ultimately, use a precision medicine-based approach to develop a therapeutic approach. Our study demonstrates that genetic screening alone is not enough.”

The research, led by scientists at the University of Leeds and The University of Texas MD Anderson Cancer Center, focused on the “Akt pathway,” a signalling pathway within cells that drives cancer formation and the spread of cancers through the body.

Under normal conditions, the cell receives external signals through a cell wall-bound receptor (FGFR2 in this study). As a result of this stimulus the receptor is ‘switched on’ inside the cell. This results in the recruitment of signalling proteins and the initiation of the Akt pathway, which is responsible for committing the cell to proliferate. In some cancerous cells, this pathway is permanently switched on. A conventional approach to diagnosing this cancer would be to look for genetic modification of the receptor (or recruited proteins), which could be responsible for maintaining the switched on state.

The new study looked at isolated cancer cells without external stimulation and found that the “Akt pathway” could be activated without genetic modifications. Two proteins; Plcγ1 (pronounced “plc-gamma-1”) and Grb2 (pronounced “grab-2”), compete for binding to FGFR2. The relative concentration of these proteins will dictate which one binds. When Plcγ1 prevails, it triggers the Akt pathway. In this way, an imbalance in the amount of the two proteins can lead to cell proliferation and cancer formation.

Dr Zahra Timsah, University Academic Fellow at the University of Leeds’ School of Molecular and Cellular Biology, , who was the lead researcher on the study, said: “This competition for binding to the receptor represents an unexpected way in which cancer can occur. We found that in cells where Grb2 is depleted, FGFR2 was vulnerable to Plcγ1 binding and that this triggered uncontrolled proliferation. Increasing the amount of Grb2 rescued this effect to maintain normal FGFR2 activity. What we think is happening is that under normal conditions the two proteins compete fairly evenly and that the Plcγ1 binding events allow useful cell housekeeping. When the proteins get imbalanced, Plcγ1 can get out of control.”

The researchers also looked at the process in a mouse model and found that Grb2 depletion results in the development of multiple tumours in the vicinity of a primary tumour, indicating that protein imbalance can have a role in metastasis, the spread of a cancer through the body. This makes sense because Plcγ1 can play a role in increasing cell movement.

Finally, the researchers looked at whether imbalance between Grb2 and Plcγ1 was predictive of the progress of ovarian cancers in patients. Measuring the levels of the proteins in patient tissues followed by database analysis of clinical information from The Cancer Genome Atlas and other sources revealed that a high level of Grb2 relative to Plcγ1 and FGFR2 was associated with a significantly more favourable prognosis than patients with elevated levels of Plcγ1.

Statistical data reveal that just under 40% of patients with a favourable balance were still alive seven years after samples were taken. Less than 10% of patients with high levels of Plcγ1 and FGFR2 binding sites survived the same length of time.

Professor Ladbury said: “From the patient’s point of view, the key findings are that these proteins are biomarkers. They could offer information to clinicians on who is going to benefit from therapy and, just as importantly, who is not. On the treatment side, the proteins’ interaction could be a valid therapeutic target: you could, for instance, target Plcγ1 to ensure it does not overwhelm the cell.”

Previous research findings have emphasised the roots of cancer in genetic mutation. Some studies have pointed to cancers that occur without genetic causes, such as through epigenetic modifications of proteins, however the present study reveals that signalling though cell wall-based receptors can occur without receptor activation and therefore that non-genetic causes may be critical to understanding cancer in large numbers of patients.

The researchers are now working with clinicians at the University of Leeds to study the same mechanisms in other forms of cancer. They are also exploring the possibility that other cell receptors could play a similar role to FGFR2 in sustaining oncogenic signalling without being activated themselves.

The research was funded by the G. Harold and Leila Y. Mathers Charitable Foundation, the National Institute of Health (NIH), the RGK Foundation and the Gilder Foundation. It involved researchers from the University of Leeds, The University of Texas MD Anderson Cancer Center and the UT Health Science Center at Houston. 

Related Links:

Yahoo News
UPI Health News
The Yorkshire Post
Science News
Health Canal
Big News Network
The Daily Mix
Biology News Net
Machines Like Us
Breitbart
Medical News Today (MNT)
Drug Discovery and Development
Demanjo
The Hans India
The Times of India

Radio: BBC Radio Leeds – Andrew Edwards
Professor John Ladbury is interviewed about the study.

Radio: BBC Radio Leeds - Liz Green
Study featured on the news round-up.

Image information: A group of ovarian cancer cells expressing low levels of the protein Grb2, making them vulnerable to cancerous proliferation.  The cell nuclei are blue and the green colour shows filaments that facilitate the cancer’s mobility.

Further information

Contact: Chris Bunting, Senior Press Officer, University of Leeds; phone +44 (0)113 343 2049 or email c.j.bunting@leeds.ac.uk.

The full paper: Z. Timsah et al., ‘Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer’  is published in Oncogene (2015), 1-11 (DOI:10.1038/onc.2015.279; URL: http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2015279a.html

 

View full article


Recent Grants

Alan Berry, Wellcome Trust (Oct 2015), £752,365

Urwin, Howard Atkinson, BBSRC (Oct 2015), £200,293

Eric Hewitt, Andrew Macdonald, Yorkshire Kidney Research Fund (Oct 2015), £46,621

Ade Whitehouse, Alison Ashcroft, Ian Carr, BBSRC (Sep 2015), £438,975

Dave Westhead, Leukaemia & Lymphoma Research Leukaemia & Lymphoma Research (Sep 2015), £430,567

Shaunna Burke, Andrea Utley, Sarah Astill, Arts Council of England (Sep 2015), £80,594

Samit Chakrabarty, Ronaldo Ichiyama, Intl Foundn for Research in Paraplegia (Aug 2015), £93,000

Anastasia Zhuravleva, BBSRC (Jul 2015), £483,019

Alex O'Neill, MRC (Jul 2015), £249,822

Ade Whitehouse, Richard Foster, Cancer Research UK (Jul 2015), £201,034

Ronaldo Ichiyama, Jim Deuchars, Sue Deuchars, Wings For Life Spinal Cord Research (Jul 2015), £123,895

Martin Stacey and colleagues in FMH, MRC (Jun 2015), £426,475

Adrian Goldman, Sarah Harris, Roman Tuma, BBSRC (Jun 2015), £420,693

Elwyn Isaac, EU (Jun 2015), £238,915

Christine Foyer, BBSRC (Jun 2015), £160,401

Adrian Goldman, EU (Jun 2015), £116,331

David Brockwell, Sheena Radford, Innovate UK (Jun 2015), £113,378

Yoselin Benitez-Alfonso, EPSRC (Jun 2015), £93,672

Michelle Peckham, Peter Knight, Thomas Edwards, BBSRC (May 2015), £404,987

Michelle Peckham, Ed White, Peter Knight, BHF (May 2015), £208,184

Dave Westhead, Sheena Radford, Alex Breeze, BBSRC (May 2015), £51,021

Steve Clapcote, Vitaflo International Ltd (May 2015), £33,703

Les Firbank, Joe Holden, Pippa Chapman, NERC (Apr 2015), £388,726

Samit Chakrabarty, David Steenson, BBSRC (Apr 2015), £120,103

Paul Millner, Gin Jose, Sarah Aickin, DSTL Porton Down (Apr 2015), £63,407

Chris Hassell, David Lewis, The Physiological Society (Apr 2015), £6,900

Andrew Tuplin, Royal Society (Mar 2015), £15,000

Yoselin Benitez-Alfonso, Royal Society (Mar 2015), £14,770

Patricija Van Oosten-Hawle, Royal Society (Mar 2015), £13,960

Stuart Egginton, BHF (Mar 2015), £272,979

Keith Hamer, Department of Energy & Climate Change (Mar 2015), £58,066

Andrew Macdonald, Yorkshire Kidney Research Fund (Mar 2015), £41,171

Les Firbank, DEFRA Dept for Env. Food & Rural Affairs (Feb 2015), £20,000

Ian Hope, Marie-Anne Shaw, BBSRC (Jan 2015), £381,998

Paul Knox, BBSRC (Jan 2015), £5,000

Andrew Peel, BBSRC (Jan 2015), £359,077

Christine Foyer, BBSRC (Jan 2015), £408,334

Dave Westhead and colleagues in Experimental Haematology, Cancer Research UK (Jan 2015), £700,521

Mike McPherson, Christoph Walti, DSTL Porton Down (Jan 2015), £625,125

Sheena Radford, Mark Harris, Peter Stockley, Alan Berry, Alex O'Neill, Thomas Edwards, Adrian Goldman, Anastasia Zhuravleva, Wellcome Trust (Jan 2015), £443,015

Alison Ashcroft, Peter Stockley, Sheena Radford, Nicola Stonehouse, David Brockwell, Darren Tomlinson, BBSRC (Jan 2015), £340,937

Bill Kunin, EU (Jan 2015), £157,490

John Colyer, Leeds Teaching Hospitals Charitable Fund (Jan 2015), £40,000

Chris Hassall, Royal Society (Dec 2014), £14,500

Ryan Seipke, Royal Society (Nov 2014), £13,700

Neil Ranson, BBSRC (Nov 2014), £355,253

Alan Berry, Wellcome Trust (Oct 2014), £749,865

Les Firbank, Joe Holden, BBSRC (Oct 2014), £210,302

Darren Tomlinson and colleagues in Chemistry and Pathology, anatomy and Tumour Biology, Dr Hadwen Trusy (Oct 2014), £194,475

Paul Knox, EU (Oct 2014), £167,229

Martin Stacey and colleagues in Medicine & Health, Pfizer (Oct 2014), £90,453

Darren Tomlinson and colleagues in Experimental Oncology, YCR (Oct 2014), £69,480

Andrew Macdonald, Jamel Mankouri, Kidney Research Fund UK (Oct 2014), £58,878

Mike McPherson and colleagues in Dentistry and Engineering, Wellcome Trust (Oct 2014), £58,437

Dave Westhead and colleagues in Experimental Haemotology, Leukaemia & Lymphoma Research (Sep 2014), £281,424

Emmanuel Paci and colleagues in Chemistry, BBSRC (Sep 2014), £636,759

Andrew Peel, BBSRC (Sep 2014), £371,598

Lars Jeuken, Stephen Evans, BBSRC (Sep 2014), £333,684

Michelle Peckham, Mark Harris, Rao Sivaprasadarao, Eileen Ingham, Nic Stonehouse, Nikita Gamper, Wellcome Trust (Sep 2014), £192,763

Recent
News

Study finds non-genetic cancer mechanism

27th July 2015

Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.


Physiological Society Oral Communication Prize Winners

17th July 2015

Ewan Fowler and Sabine Lotteau from the Cardiovascular, Sport and Exercise Sciences group (School of Biomedical Sciences) have been awarded the Physiological Society’s Oral Communication Prizes


Age doesn’t dull damselflies' love lives

16th July 2015

Aging damselflies never lose their libidos and are just as likely as younger competitors to mate.


The University of Leeds is investing in 250 new academic fellowships.

1st July 2015

Are you one of the 250 Great Minds we are looking for?


Leeds academics recognised for teaching excellence

11th June 2015

Two University of Leeds academics have received a prestigious teaching award, a National Teaching Fellowship.


The Quest to Engineer the Perfect Potato

8th June 2015

Researchers in the U.K. aim for a new commercial potato that resists many of the worst vulnerabilities of potato crops around the world.


University of Leeds announces £17m Astbury BioStructure Laboratory

3rd June 2015

The new facility will provide the University's internationally renowned Astbury Centre for Structural Molecular Biology with instruments for Electron Microscopy and Nuclear Magnetic Resonance that are competitive with the very best in the world.


The Cutlers Surgical Prize

18th May 2015

Dr Dan Saleh and Dr Andrea Utley win one of the most prestigious surgical prizes with their jointly developed Yorkshire Micro Forcep.


Leeds academics recruited to find pigs breakthrough

12th May 2015

A FIELD trial which is intended to lead to improved productivity in the British pig industry is being led by a group of academics in West Yorkshire.


Fascination of Plants Day 2015

7th May 2015

Plants are essential for life, providing everything, from food to energy, clothing and life-saving drugs.

 


Prestigious Royal Society of Chemistry award for Leeds research

7th May 2015

A research team led by Professors Alison Ashcroft and Sheena Radford joins an illustrious list of winners of the Royal Society of Chemistry's Rita and John Cornforth Award.


Impact
Stories

Professor Ian Chopra and Dr Alex O'Neill have shown that high levels of FA prevent the development of resistant bacteria.

The Ponnambalam laboratory undertakes research relating to cardiovascular diseases and cancer.

Research by Dr Simon Goodman shows how large the effect of human activity has been on the Caspian Seal.

Badrilla is working with outstanding academic collaborators to develop new technologies for calibration of immunoassays.

All impact stories